The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial
Open accessAbstract
Importance: Although current guidelines suggest the use of regional citrate anticoagulation (which involves the addition of a citrate solution to the blood before the filter of the extracorporeal dialysis circuit) as first-line treatment for continuous kidney replacement therapy in critically ill patients, the evidence for this recommendation is based on few clinical trials and meta-analyses. Objective: To determine the effect of regional citrate anticoagulation, compared with systemic heparin anticoagulation, on filter life span and mortality. Design, Setting, and Participants: A parallel-group, randomized multicenter clinical trial in 26 centers across Germany was conducted between March 2016 and December 2018 (final date of follow-up, January 21, 2020). The trial was terminated early after 596 critically ill patients with severe acute kidney injury or clinical indications for initiation of kidney replacement therapy had been enrolled. Interventions: Patients were randomized to receive either regional citrate anticoagulation (n = 300), which consisted of a target ionized calcium level of 1.0 to 1.40 mg/dL, or systemic heparin anticoagulation (n = 296), which consisted of a target activated partial thromboplastin time of 45 to 60 seconds, for continuous kidney replacement therapy. Main Outcomes and Measures: Coprimary outcomes were filter life span and 90-day mortality. Secondary end points included bleeding complications and new infections. Results: Among 638 patients randomized, 596 (93.4%) (mean age, 67.5 years; 183 [30.7%] women) completed the trial. In the regional citrate group vs systemic heparin group, median filter life span was 47 hours (interquartile range [IQR], 19-70 hours) vs 26 hours (IQR, 12-51 hours) (difference, 15 hours [95% CI, 11 to 20 hours]; P < .001). Ninety-day all-cause mortality occurred in 150 of 300 patients vs 156 of 296 patients (Kaplan-Meier estimator percentages, 51.2% vs 53.6%; unadjusted difference, -2.4% [95% CI, -10.5% to 5.8%]; unadjusted hazard ratio, 0.91 [95% CI, 0.72 to 1.13]; unadjusted P = .38; adjusted difference, -6.1% [95% CI, -12.6% to 0.4%]; primary adjusted hazard ratio, 0.79 [95% CI, 0.63 to 1.004]; primary adjusted P = .054). Of 38 prespecified secondary end points, 34 showed no significant difference. Compared with the systemic heparin group, the regional citrate group had significantly fewer bleeding complications (15/300 [5.1%] vs 49/296 [16.9%]; difference, -11.8% [95% CI, -16.8% to -6.8%]; P < .001) and significantly more new infections (204/300 [68.0%] vs 164/296 [55.4%]; difference, 12.6% [95% CI, 4.9% to 20.3%]; P = .002). Conclusions and Relevance: Among critically ill patients with acute kidney injury receiving continuous kidney replacement therapy, anticoagulation with regional citrate, compared with systemic heparin anticoagulation, resulted in significantly longer filter life span. The trial was terminated early and was therefore underpowered to reach conclusions about the effect of anticoagulation strategy on mortality. Trial Registration: ClinicalTrials.gov Identifier: NCT02669589.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
De Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802639 · Cited by 1,759
Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902413 · Cited by 1,473
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
Kashani, K., Al-Khafaji, A., Ardiles, T., Artigas, A., Bagshaw, S. M., Bell, M., Bihorac, A., Birkhahn, R., Cely, C. M., Chawla, L. S., et al. (2013) · Critical Care · doi:10.1186/cc12503 · Cited by 1,362
Self-citationZarbock, A., Kellum, J. A., Schmidt, C., Van Aken, H., Wempe, C., Pavenstädt, H., Boanta, A., Gerß, J., & Meersch, M. (2016) · JAMA · doi:10.1001/jama.2016.5828 · Cited by 1,143
Self-citationTiming of renal-replacement therapy in patients with acute kidney injury and sepsis.
Barbar, S. D., Clere-Jehl, R., Bourredjem, A., Hernu, R., Montini, F., Bruyère, R., Lebert, C., Bohé, J., Badie, J., Eraldi, J.-P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803213 · Cited by 777
Bagshaw, S. M., Laupland, K. B., Boiteau, P. J. E., & Godinez-Luna, T. (2005) · Journal of Critical Care · doi:10.1016/j.jcrc.2005.01.001 · Cited by 379
Self-citationMonchi, M., Berghmans, D., Ledoux, D., Canivet, J.-L., Dubois, B., & Damas, P. (2004) · Intensive Care Medicine · doi:10.1007/s00134-003-2047-x · Cited by 369
Renal Replacement Therapy in Patients With Acute Renal Failure: A Systematic Review
Pannu, N., Klarenbach, S., Wiebe, N., Manns, B., Tonelli, M., & Alberta Kidney Disease Network, F. T. (2008) · JAMA · doi:10.1001/jama.299.7.793 · Cited by 351
Citrate anticoagulation for continuous venovenous hemofiltration*
Oudemans-van Straaten, H. M., Bosman, R. J., Koopmans, M., van der Voort, P. H. J., Wester, J. P. J., van der Spoel, J. I., Dijksman, L. M., & Zandstra, D. F. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181953c5e · Cited by 332
Kutsogiannis, D. J., Gibney, R. T. N., Stollery, D., & Gao, J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00342.x · Cited by 294
Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients
Kramer, L., Bauer, E., Joukhadar, C., Strobl, W., Gendo, A., Madl, C., & Gangl, A. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000084871.76568.e6 · Cited by 276
Hetzel, G. R., Schmitz, M., Wissing, H., Ries, W., Schott, G., Heering, P. J., Isgro, F., Kribben, A., Himmele, R., Grabensee, B., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq575 · Cited by 246
van de Wetering, J., Westendorp, R. G., van der Hoeven, J. G., Stolk, B., Feuth, J. D., & Chang, P. C. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v71145 · Cited by 202
Gattas, D. J., Rajbhandari, D., Bradford, C., Buhr, H., Lo, S., & Bellomo, R. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000001004 · Cited by 193
Wu, M.-Y., Hsu, Y.-H., Bai, C.-H., Lin, Y.-F., Wu, C.-H., & Tam, K.-W. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.11.030 · Cited by 190
Prevalence of Hypophosphatemia in Sepsis and Infection: The Role of Cytokines
Barak, V., Schwartz, A., Kalickman, I., Nisman, B., Gurman, G., & Shoenfeld, Y. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00275-1 · Cited by 187
Schilder, L., Nurmohamed, A. S., Bosch, F. H., Purmer, I. M., den Boer, S. S., Kleppe, C. G., Vervloet, M. G., Beishuizen, A., Girbes, A. R. J., ter Wee, P. M., et al. (2014) · Critical Care · doi:10.1186/s13054-014-0472-6 · Cited by 180
Unverzagt, S., Prondzinsky, R., & Peinemann, F. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.05.016 · Cited by 172
Zhang, Z., & Hongying, N. (2012) · Intensive Care Medicine · doi:10.1007/s00134-011-2438-3 · Cited by 162
Gritters, M., Grooteman, M. P. C., Schoorl, M., Schoorl, M., Bartels, P. C. M., Scheffer, P. G., Teerlink, T., Schalkwijk, C. G., Spreeuwenberg, M., & Nubé, M. J. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi069 · Cited by 161
Introduction to the Ninth Edition
Guyatt, G. H., Akl, E. A., Crowther, M., Schünemann, H. J., Gutterman, D. D., & Lewis, S. Z. (2012) · Chest · doi:10.1378/chest.11-2286 · Cited by 159
Betjes, M. G. H., van Oosterom, D., van Agteren, M., & van de Wetering, J. (2007) · Journal of Nephrology · doi:10.1093/joneph/20.5.602 · Cited by 128
Follow-up Care in Acute Kidney Injury: Lost in Transition
Silver, S. A., & Siew, E. D. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.05.008 · Cited by 83
Durão, M. S., Monte, J. C. M., Batista, M. C., de Oliveira, M. F. A., Iizuka, I. J., dos Santos, B. F. C., Pereira, V. G., Cendoroglo, M. N., & dos Santos, O. F. P. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b9100 · Cited by 68
Cited by
Ostermann, M., Lumlertgul, N., Jeong, R., See, E., Joannidis, M., & James, M. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02385-7 · Cited by 396
Karvellas, C. J., Lambert, J., Ouyang, T., Bagshaw, S. M., Cullaro, G., Fricker, Z., Frederick, T., Goldstein, S. L., House, A. A., Juncos, L. A., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007363
Self-citation
Metadata
- Authors
- Zarbock, A., Küllmar, M., Kindgen-Milles, D., Wempe, C., Gerss, J., Brandenburger, T., Dimski, T., Tyczynski, B., Jahn, M., Mülling, N., Mehrländer, M., Rosenberger, P., Marx, G., Simon, T. P., Jaschinski, U., Deetjen, P., Putensen, C., Schewe, J.-C., Kluge, S., Jarczak, D., Slowinski, T., Bodenstein, M., Meybohm, P., Wirtz, S., Moerer, O., Kortgen, A., Simon, P., Bagshaw, S. M., Kellum, J. A., Meersch, M., & RICH Investigators and the Sepnet Trial Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-10-27
- Volume
- 324
- Issue
- 16
- Pages
- 1629
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3094020901
- Cited by
- 366
- References
- 29
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.